USP7 and liver cancer: It has been reported that both USP7 and USP22 protect PD-L1 from ubiquitination-mediated degradation in cancers including gastric cancer, lung adenocarcinoma, and liver cancer (20-23), neither of which was enriched in our screening (Figure 1B).